Lowest Price Guaranteed From USD 2,499
Published
July 2017
Pages
278
View Count
5114
Example Insights
Report Description
The growing pipeline of biological drugs has resulted in a continuous increase in the demand for different types of cell lines. More than 650 biologics have been approved till date, and over 1,500 are under clinical development. Additionally, the loss of patent exclusivity of several biologics in the coming years is likely to be followed by the entry of numerous biosimilars as many companies compete to grab a share of already established drug markets. The importance of cell lines in other areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, has resulted in further increase in the demand for different types of cell lines. The rapid progression of biological drug candidates through various phases of development, coupled with the growing demand of cell lines for other applications, presents significant opportunities to cell line development service providers.
The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players are contributing to the production of GMP and non-GMP grade cell lines that are obtained from mammalian, microbial, insect-derived, avian, marine, reptilian and other sources. Stakeholders have entered into multiple partnerships / collaborations in order to improve and scale-up production processes, and expand their capabilities. Considering the heightened activity in this domain, we believe the market is likely to evolve at a steady pace in the mid to long term, driven primarily by the increasing demand for cell lines, and advances in technology platforms and production methodologies.
Scope of the Report
The ‘Cell Line Development Services Market, 2017 - 2027’ report provides an extensive study of the rapidly growing market of cell lines. Cells obtained from mammalian and microbial sources are widely used for the development and manufacturing of biotherapeutic products, such as recombinant proteins, antibodies and vaccines. Mammalian cell lines, owing to their inherent high productivity and ability to produce complex biopharmaceuticals, are relatively more preferred. At the same time, microbial cell lines are also widely used due to their less complex nature, low cost and high versatility.
As mentioned earlier, in addition to the large number of biologics that are already available in market, many are under various stages of development. In fact, close to 50% of product candidates in the current development pipeline are in the preclinical stage. Moreover, a number of important biologics, such as Aransep®, Avastin®, Herceptin®, HUMIRA®, Neulasta® and REMICADE®, are approaching patent expiration, and several companies are already engaged in the development of biosimilars and biobetters. As of May 2017, five biosimilars in the US and 28 in Europe have been approved. In addition to the US and EU, several companies based in Asia are also focused on the development of biosimilars. These developments have led to an upward surge in the demand for highly-productive and stable cell lines. High yielding cell lines, capable of producing top quality biopharmaceuticals, help in significantly reducing development and manufacturing costs. Hence, several companies have designed and developed innovative systems / technologies / proprietary manufacturing processes in order to optimize manufacturing costs and production timelines of the overall cell line development process. In addition to development-related services, several cell line manufacturers provide other services related to cell lines as a part of their respective services portfolios; examples of these services include cell line characterization, cell banking, cell bank characterization, process development and commercialization of reagents / equipment. It is also important to highlight that some of these companies offer cGMP production of biologics and fill / finish of end products as well.
This study presents an in-depth analysis of companies that are actively involved in providing cell line development services. In addition to other elements, the study features:
We have provided informed estimates of the size of the market in the short to mid-term and long term for the period 2017-2027. To account for the uncertainties associated with the development of cell lines and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The insights presented in this study were also influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).
Contents
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the cell line development services market over the coming decade.
Chapter 3 provides a general introduction to the various types of cell lines. It includes a detailed discussion on the sources, selection and maintenance conditions, key features, applications and limitations of currently available cell lines. The chapter also provides a brief description of cell line characterization and cell banking services.
Chapter 4 identifies the contract service providers that are actively involved in the development of cell lines. The chapter provides details on the cell line development capabilities of these organizations, geographic location of their facilities, information on the proprietary technology (if any) used by the company for cell line development, type of cell lines produced by the company (recombinant, hybridoma and primary) and applications of the cell lines (such as for R&D activities, biomanufacturing, diagnostics and tissue engineering). The chapter also provides the distribution of companies based on the other services that they offer; these include cell line characterization, cell bank characterization, cell banking, process development, cGMP manufacturing of biologics, fill / finish and commercialization of reagents / equipment.
Chapter 5 presents a detailed analysis of the cell line development services market landscape. It features a schematic representation on world map, highlighting the key geographical locations of cell line manufacturing facilities. Further, we have provided a heat map analysis representing the distribution of companies on the basis of their location, year of establishment and cell line development capabilities. The chapter also provides a logo landscape of companies based on their size (employee base) and source of cell lines produced.
Chapter 6 offers detailed profiles of contract cell line development service providers that have developed proprietary technology / technologies for the production of cell lines. Each profile provides an overview of the company, its financial performance, details on its proprietary technology / technologies, information on its cell line manufacturing capabilities, recent investments / expansions, relevant collaborations and partnerships that have been inked over the last few years, and a comprehensive future outlook.
Chapter 7 features profiles of additional players that offer cell line characterization, cell banking and cGMP production services, apart from cell line development services. However, the companies included in this chapter have not developed any proprietary technology / technologies for producing cell lines.
Chapter 8 features profiles of key non-industry players (cell line repositories) that are playing an active role in providing cell line development services. Each profile provides a brief overview of the organization and the services it offers.
Chapter 9 presents a 10-year sales forecast, highlighting the likely growth of the market for cell lines development services. We have segregated the broader opportunity by source of cell lines (mammalian, microbial, insect-derived and others), regions (North America, Europe, Asia and the Rest of the World) and grade of cell lines (GMP and non-GMP). Our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic forecast scenarios.
Chapter 10 presents insights from a survey that we conducted for this study. The participants, who were primarily members of the Senior Management or CXO level representatives, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.
Chapter 11 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and trends that are likely to determine the future evolution of this segment of the industry.
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented detailed transcripts of discussions held with Fan Chen (VP BioProcessing, LakePharma), Michael Pointek(Managing Director, Artes Biotechnology), Nienke Smits (Business Development, ModiQuest) and Oscar Hoogteijling (Business Development Manager, Bioceros).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 14 is an appendix,which contains the list of companies and organizations that have been mentioned in the report.
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Introduction to Cell Culture
3.2.1. Primary Cell Culture
3.2.2. Secondary Cell Culture
3.3. Types of Cell Lines
3.3.1. Recombinant Cell Lines
3.3.2. Hybridoma Cell Lines
3.3.3. Finite Cell Lines
3.3.4. Continuous Cell Lines
3.4. Sources of Cell Lines
3.4.1. Mammalian
3.4.2. Non-Mammalian
3.5. Selection of a Cell Line
3.6. Maintenance of Cell Lines
3.7. Key Features of a Cell Lines
3.8. Applications of Cell Lines
3.9. Key Concerns Associated with Cell Lines
3.10. Cell Line Characterization
3.11. Cell Banking
3.12. Need for Outsourcing Cell Line Related Operations
4. Market Overview
4.1. Chapter Overview
4.2. Cell Line Development Services Providers: Market Landscape
4.2.1. Distribution by Location of Manufacturing Facility
4.2.2. Distribution by Source of Cell Lines
4.2.3. Distribution by Type and Applications of Cell Lines
4.2.4. Distribution by Other Services Related to Cell Line Development
5. Competitive Landscape
5.1. Chapter Overview
5.2. Regional Analysis
5.3. Heat Map Analysis
5.4. Analysis by Source of Cell Lines and Size of Company
6. Company Profiles of Key Players
6.1. Chapter Overview
6.2. Abzena
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Cell Line Development Services and Technology Platforms
6.2.4. Manufacturing Facilities
6.2.5. Recent Developments
6.2.5.1. Collaborations
6.2.5.2. Investments and Expansions
6.2.5.3. Acquisitions
6.2.6. Future Outlook
6.3. Batavia Biosciences
6.3.1. Company Overview
6.3.2. Cell Line Development Services and Technology Platforms
6.3.3. Manufacturing Facilities
6.3.4. Recent Developments
6.3.4.1. Collaborations
6.3.4.2. Investments and Expansions
6.3.5. Future Outlook
6.4. Celonic
6.4.1. Company Overview
6.4.2. Cell Line Development Services and Technology Platforms
6.4.3. Manufacturing Facilities
6.4.4. Recent Developments
6.4.4.1. Collaborations
6.4.4.2. Investments and Expansions
6.4.5. Future Outlook
6.5. CMC Biologics
6.5.1. Company Overview
6.5.2. Cell Line Development Services and Technology Platforms
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments
6.5.4.1. Collaborations
6.5.4.2. Investments and Expansions
6.5.4.3. Acquisitions
6.5.5. Future Outlook
6.6. Cobra Biologics
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Cell Line Development Services and Technology Platforms
6.6.4. Recent Developments
6.6.4.1. Collaborations
6.6.4.2. Investments and Expansions
6.6.5. Future Outlook
6.7. Hyprocell
6.7.1. Company Overview
6.7.2. Cell Line Development Services and Technology Platforms
6.7.3. Future Outlook
6.8. LFB Biomanufacturing
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Cell Line Development Services and Technology Platforms
6.8.4. Manufacturing Facilities
6.8.5. Recent Developments
6.8.5.1. Collaborations
6.8.5.2. Investments and Expansions
6.8.6. Future Outlook
6.9. Lonza
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Cell Line Development Services and Technology Platforms
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments
6.9.5.1. Collaborations
6.9.5.2. Investments and Expansions
6.9.5.3. Acquisitions
6.9.6. Future Outlook
6.10. ProBioGen
6.10.1. Company Overview
6.10.2. Cell Line Development Services and Technology Platforms
6.10.3. Recent Developments
6.10.3.1. Collaborations
6.10.3.2. Investments and Expansions
6.10.4. Future Outlook
6.11. Selexis
6.11.1. Company Overview
6.11.2. Cell Line Development Services and Technology Platforms
6.11.3. Recent Developments
6.11.3.1. Collaborations
6.11.3.2. Investments and Expansions
6.11.4. Future Oulook
6.12. trenzyme
6.12.1. Company Overview
6.12.2. Cell Line Development Services and Technology Platforms
6.12.3. Recent Developments
6.12.3.1. Collaborations
6.12.4. Future Outlook
7. Company Profiles of Additional Players
7.1. Chapter Overview
7.2. ARTES Biotechnology
7.3. Bioceros
7.4. Biovian
7.5. Charles River Laboratories
7.6. EuBiologics
7.7. Inno Biologics
7.8. LakePharma
7.9. ModiQuest Research
7.10. Nanotherapeutics
7.11. Oxford Genetics
7.12. RD-Biotech
7.13. Syngene International
7.14. TPG Biologics
7.15. WuXi Biologics
8. Cell Line Repositories
8.1. Chapter Overview
8.2. American Type Culture Collection (ATCC)
8.2.1. Overview
8.2.2. Services Portfolio
8.3. Leibniz Institute DSMZ
8.3.1. Overview
8.3.2. Services Portfolio
8.4. European Collection of Authenticated Cell Cultures (ECACC)
8.4.1. Overview
8.4.2. Services Portfolio
8.5. Coriell Institute for Medical Research
8.5.1. Overview
8.5.1.1. Services Portfolio
9. Market Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Input Data Tables and Assumptions
9.4. Cell Line Development Services Market Outlook, 2017-2027
9.5. Distribution of Future Opportunity by Source of Cell Lines
9.5.1. Cell Line Development Services Market for Mammalian Cells, 2017-2027
9.5.2. Cell Line Development Services Market for Microbial Cells, 2017-2027
9.5.3. Cell Line Development Services Market for Insect Cells, 2017-2027
9.5.4. Cell Line Development Services Market for Other Cells, 2017-2027
9.6. Distribution of Future Opportunity by Geography
9.6.1. Cell Line Development Services Market in North America, 2017-2027
9.6.2. Cell Line Development Services Market in the EU, 2017-2027
9.6.3. Cell Line Development Services Market in Asia, 2017-2027
9.6.4. Cell Line Development Services Market in the Rest of the World, 2017-2027
9.7. Distribution of Future Opportunity by Grade of Cell Lines
9.7.1. Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027
9.7.2. Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027
10. Survey Analysis
10.1. Chapter Overview
10.1.1. Overview of Respondents
10.1.2. Seniority Level of Respondents
10.2. Type of Cell Lines
10.3. Source of Cell Lines
10.4. Applications of Cell Lines
10.5. Cell Line Characterization Services
10.6. Cell Banking Services
10.7. Biologics Manufacturing Services
10.8. Fill / Finish Services
11. Conclusion
11.1. Mammalian and Microbial Cell Lines Continue to be Preferred Over those Derived from Other Sources
11.2. Cell Line Characterization, Cell Banking, Process Development and Other Affiliated Services also form an Important Part of the Services Portfolio of Most of the Players
11.3. Innovative Technologies Developed to Optimize and Scale-up the Overall Cell Line Development Process are Emerging as Key Enablers to Future Growth
11.4. Companies Headquartered in the US and EU Dominate the Market Landscape; Asia is Emerging as an Alternative Destination for Provision of such Services
11.5. The Market Continues to Witness Significant Partnership Activity Indicating a Lucrative Future Potential
11.6. Escalating Biomanufacturing Activities and R&D Initiatives are Expected to Act as Key Drivers of the Market
11.7. Overall, the Cell Line Development Services Market is Poised to Grow at a Steady Pace in the Coming Decade
12. Interview Transcripts
12.1. Chapter Overview
12.2. Fan Chen, Vice President BioProcessing, LakePharma
12.3. Michael Pointek, Managing Director, ARTES Biotechnology
12.4. Nienke Smits, Business Development, ModiQuest
12.5. Oscar Hoogteijling, Business Development Manager, Bioceros
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
Figure 3.1 Primary and Secondary Cell Culture
Figure 3.2 Recombinant Cell Line Development
Figure 3.3 Hybridoma Cell Line Development
Figure 3.4 Sources of Non-Mammalian Cell Lines
Figure 3.5 Applications of Cell Lines
Figure 3.6 Factors Affecting the Utility of Cell Lines
Figure 4.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
Figure 4.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
Figure 4.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Figure 4.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
Figure 4.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
Figure 4.6 Cell Line Development Services Providers: Distribution by Other Related Services
Figure 5.1 Regional Analysis: Distribution by Location of Manufacturing Facility
Figure 5.2 Heat Map Analysis: Distribution by Location of Manufacturing Facility and Year of Establishment
Figure 5.3 Cell Line Development Services Providers (North America): Distribution by Source of Cell Lines and Size of Company
Figure 5.4 Cell Line Development Services Providers (EU): Distribution by Source of Cell Lines and Size of Company
Figure 5.5 Cell Line Development Services Providers (Asia): Distribution by Source of Cell Lines and Size of Company
Figure 6.1 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
Figure 6.2 Abzena: Revenues by Business Divisions, FY 2015-FY 2016 (EUR Million)
Figure 6.3 Celonic: CHOvolution Technology
Figure 6.4 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
Figure 6.5 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
Figure 6.6 LFB Biomanufacturing: Cell Line Development Process
Figure 6.7 Lonza: Custom Contract Manufacturing Services
Figure 6.8 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
Figure 6.9 GS Gene Expression System: Working Principle
Figure 6.10 Selexis: Cell Line Development Process
Figure 6.11 trenzyme: Cell Line Development Process
Figure 8.1 ATCC: Services Portfolio
Figure 8.2 Leibniz Institute DSMZ: Biological Material Collection
Figure 8.3 ECACC: Biological Material Collection
Figure 8.4 ECACC: Services Portfolio
Figure 8.5 Coriell Institute of Medical Research: Operating Segments
Figure 8.6 Coriell Institute for Medical Research: Services Portfolio
Figure 9.1 Cell Line Development Services Market, 2017-2027 (USD Billion)
Figure 9.2 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
Figure 9.3 Cell Line Development Services Market for Mammalian Cells, 2017-2027 (USD Billion)
Figure 9.4 Cell Line Development Services Market for Microbial Cells, 2017-2027 (USD Million)
Figure 9.5 Cell Line Development Services Market for Insect Cells, 2017-2027 (USD Million)
Figure 9.6 Cell Line Development Services Market for Other Cells, 2017-2027 (USD Million)
Figure 9.7 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
Figure 9.8 Cell Line Development Services Market in North America, 2017-2027 (USD Million)
Figure 9.9 Cell Line Development Services Market in the EU, 2017-2027 (USD Million)
Figure 9.10 Cell Line Development Services Market in Asia, 2017-2027 (USD Million)
Figure 9.11 Cell Line Development Services Market in the Rest of the World, 2017-2027 (USD Million)
Figure 9.12 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
Figure 9.13 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027 (USD Billion)
Figure 9.14 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027 (USD Million)
Figure 10.1 Survey Analysis: Distribution by Location of Organization
Figure 10.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Figure 10.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 10.4 Survey Analysis: Distribution by Types of Cell Lines
Figure 10.5 Survey Analysis: Distribution by Source of Cell Lines
Figure 10.6 Survey Analysis: Distribution by Applications of Cell Lines
Figure 10.7 Survey Analysis: Cell Line Characterization Services
Figure 10.8 Survey Analysis: Cell Banking Services
Figure 10.9 Survey Analysis: Biologics Manufacturing Services
Figure 10.10 Survey Analysis: Fill / Finish Services
Figure 11.1 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
Figure 11.2 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
Figure 11.3 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines
Table 3.1 Comparison of Properties of Finite and Continuous Cell line
Table 3.2 Human Cell Lines and Therapeutic Protein Products
Table 3.3 Cell Lines and Viral Vaccine Products
Table 4.1 Cell Line Development Services Providers: List of Companies
Table 4.2 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Table 4.3 Cell Line Development Services Providers: Distribution by Type and Application of Cell Lines
Table 4.4 Cell Line Development Services Providers: Distribution by Other Related Services
Table 6.1 CMC Biologics: Mammalian and Microbial cGMP Manufacturing Capabilities
Table 9.1 Input Data and Assumptions: Distribution of Cell Line Development Services Providers by Size of the Company and Grade of Cell Lines
Table 9.2 Input Data and Assumptions: Distribution of Price of Cell Lines by Source and Grade of Cell Lines
Table 9.3 Input Data and Assumptions: Distribution of Number of Projects Undertaken by Size of Company
Table 9.4 Input Data and Assumptions: Distribution of Source of Cell Lines by Percentage of Biopharmaceuticals Produced
Table 10.1 Survey Responses: Overview of the Respondents
Table 10.2 Survey Responses: Seniority Level of Respondents
Table 10.3 Survey Responses: Types of Cell Lines
Table 10.4 Survey Responses: Source of Cell Lines
Table 10.5 Survey Responses: Applications of Cell Lines
Table 10.6 Survey Responses: Cell Line Characterization Services
Table 10.7 Survey Responses: Cell Banking Services
Table 10.8 Survey Responses: Biologics Manufacturing Services
Table 10.9 Survey Responses: Fill / Finish Services
Table 13.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
Table 13.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
Table 13.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Table 13.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
Table 13.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
Table 13.6 Cell Line Development Services Providers: Distribution by Other Related Services
Table 13.7 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
Table 13.8 Abzena: Revenues by Business Divisions, FY 2015-2016 (EUR Million)
Table 13.9 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
Table 13.10 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
Table 13.11 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
Table 13.12 Cell Line Development Services Market, 2017-2027: Base Scenario (USD Billion)
Table 13.13 Cell Line Development Services Market, 2017-2027: Conservative Scenario (USD Billion)
Table 13.14 Cell Line Development Services Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.15 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
Table 13.16 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Base Scenario (USD Billion)
Table 13.17 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Conservative Scenario (USD Billion)
Table 13.18 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.19 Cell Line Development Services Market for Microbial Cells, 2017-2027: Base Scenario (USD Million)
Table 13.20 Cell Line Development Services Market for Microbial Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.21 Cell Line Development Services Market for Microbial Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.22 Cell Line Development Services Market for Insect Cells, 2017-2027: Base Scenario (USD Million)
Table 13.23 Cell Line Development Services Market for Insect Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.24 Cell Line Development Services Market for Insect Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.25 Cell Line Development Services Market for Other Cells, 2017-2027: Base Scenario (USD Million)
Table 13.26 Cell Line Development Services Market for Other Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.27 Cell Line Development Services Market for Other Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.28 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
Table 13.29 Cell Line Development Services Market in North America, 2017-2027: Base Scenario (USD Million)
Table 13.30 Cell Line Development Services Market in North America, 2017-2027: Conservative Scenario (USD Million)
Table 13.31 Cell Line Development Services Market in North America, 2017-2027: Optimistic Scenario (USD Million)
Table 13.32 Cell Line Development Services Market in the EU, 2017-2027: Base Scenario (USD Million)
Table 13.33 Cell Line Development Services Market in the EU, 2017-2027: Conservative Scenario (USD Million)
Table 13.34 Cell Line Development Services Market in the EU, 2017-2027: Optimistic Scenario (USD Million)
Table 13.35 Cell Line Development Services Market in Asia, 2017-2027: Base Scenario (USD Million)
Table 13.36 Cell Line Development Services Market in Asia, 2017-2027: Conservative Scenario (USD Million)
Table 13.37 Cell Line Development Services Market in Asia, 2017-2027: Optimistic Scenario (USD Million)
Table 13.38 Cell Line Development Services Market in the Rest of the World, 2017-2027: Base Scenario (USD Million)
Table 13.39 Cell Line Development Services Market in the Rest of the World, 2017-2027: Conservative Scenario (USD Million)
Table 13.40 Cell Line Development Services Market in the Rest of the World, 2017-2027: Optimistic Scenario (USD Million)
Table 13.41 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
Table 13.42 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Base Scenario (USD Billion)
Table 13.43 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Billion)
Table 13.44 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.45 Cell Line Development Services Market for Non-GMP Cell Lines, 2017-2027: Base Scenario (USD Million)
Table 13.46 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Million)
Table 13.47 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Million)
Table 13.48 Survey Analysis: Distribution by Location of Organization
Table 13.49 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 13.50 Survey Analysis: Distribution by Seniority Level of Respondents
Table 13.51 Survey Analysis: Distribution by Type of Cell Lines
Table 13.52 Survey Analysis: Distribution by Source of Cell Lines
Table 13.53 Survey Analysis: Distribution by Applications of Cell Lines
Table 13.54 Survey Analysis: Cell Line Characterization Services
Table 13.55 Survey Analysis: Cell Banking Services
Table 13.56 Survey Analysis: Biologics Manufacturing Services
Table 13.57 Survey Analysis: Fill / Finish Services
Table 13.58 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
Table 13.59 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
Table 13.60 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES